{
  "thread": {
    "uuid": "7faf906fe37ace8a04b0910252e3b5cc58874892",
    "url": "https://www.zhitongcaijing.com/content/detail/1273587.html",
    "site_full": "www.zhitongcaijing.com",
    "site": "zhitongcaijing.com",
    "site_section": "https://zhitongcaijing.com/content/hkstock.html",
    "site_categories": [],
    "section_title": "推荐-智通财经网",
    "site_title": "智通财经网-连线全球资本市场",
    "title": "最高看涨至12.70港元！大摩、中金齐看好先声药业(02096) 创新药增长潜力可期",
    "title_full": "最高看涨至12.70港元！大摩、中金齐看好先声药业(02096) 创新药增长潜力可期",
    "published": "2025-04-03T01:48:51.443+03:00",
    "replies_count": 0,
    "participants_count": 0,
    "site_type": "news",
    "country": "HK",
    "main_image": "",
    "performance_score": 0,
    "domain_rank": 189173,
    "domain_rank_updated": "2025-04-01T00:00:00.000+03:00",
    "licensing_agency": [],
    "social": {
      "facebook": {
        "likes": 0,
        "comments": 0,
        "shares": 0
      },
      "vk": {
        "shares": 0
      }
    }
  },
  "uuid": "7faf906fe37ace8a04b0910252e3b5cc58874892",
  "url": "https://www.zhitongcaijing.com/content/detail/1273587.html",
  "ord_in_thread": 0,
  "author": null,
  "published": "2025-04-03T01:48:51.443+03:00",
  "title": "最高看涨至12.70港元！大摩、中金齐看好先声药业(02096) 创新药增长潜力可期",
  "text": "智通财经APP获悉，2025年4月2日，摩根士丹利发表研报将先声药业（02096）目标价从8.70港元上调至9.50港元，并同步调高乐观情景下目标价至12.70港元（原11.80港元），给予“增持”评级。\n据悉，先声药业近日公布2024年业绩，符合市场预期，收入66.35亿元，同比增长0.4%；归母净利润7.33亿元，同比增长2.6%，经调整归母净利润10.18亿元，同比增长41.6%。\n对此，中金发布研报称，基本维持2025年和2026年盈利预测不变，维持先声药业(02096)跑赢行业评级和8.80港元目标价，对应17.4倍2025年市盈率和15.6倍2026年市盈率。公司多款创新早研产品(来自公司ADC/TCE/小分子平台)积极推进临床，中金认为具备license out潜力，期待今年取得积极进展。\n交银国际发布研报称，上调先声药业2025-26年经调整净利润预测6-8%，主要反映更乐观的利润率改善空间。2H24公司业绩增速如期迎来复苏，预计这一趋势将延续至2025-27年，公司将迎来6款创新药上市，同时创新技术平台有望持续产出BD出海机会，上调目标价至11.2港元，看好业绩复苏和BD催化估值修复，继续将公司选为行业重点推荐标的之一。",
  "highlightText": "",
  "highlightTitle": "",
  "highlightThreadTitle": "",
  "language": "chinese",
  "sentiment": "positive",
  "categories": [
    "Science and Technology",
    "Economy, Business and Finance",
    "Health"
  ],
  "topics": [
    "Science and Technology->biomedical science",
    "Science and Technology->economics",
    "Science and Technology->medical research",
    "Economy, Business and Finance->business reporting and performance",
    "Economy, Business and Finance->financial and economic news",
    "Health->health organisation",
    "Health->drug rehabilitation"
  ],
  "ai_allow": true,
  "has_canonical": false,
  "breaking": false,
  "webz_reporter": false,
  "external_links": [],
  "entities": {
    "persons": [],
    "locations": [],
    "organizations": []
  },
  "syndication": {
    "syndicated": null,
    "syndicate_id": null,
    "first_syndicated": false
  },
  "trust": {
    "categories": [],
    "bias": null
  },
  "rating": null,
  "crawled": "2025-04-03T01:48:51.443+03:00",
  "updated": "2025-04-03T01:48:51.443+03:00"
}